Yan Wang

14PUBLICATIONS
29CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Mar 24, 2026
RFC4 drives temozolomide resistance in glioblastoma by activating STK38-BECN1-dependent autophagy.

Min Mao, Hang Ji, Wen-Qian Yu

|Jan 17, 2024
FANCD2 deficiency sensitizes SHH medulloblastoma to radiotherapy via ferroptosis.

Hong Zhou, Yan-Xia Wang, Min Wu

|Apr 14, 2022
Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma.

Yue-Liang Yao, Yan-Xia Wang, Fei-Cheng Yang

|Mar 11, 2022
Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas.

Yan-Xia Wang, Haibo Wu, Yong Ren

Pageof 3